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human oocytes.
Design: Case–control study using epigenetic data.
Setting: Two collaborating university departments.
Patient(s): Eleven IVM newborns and 19 controls, conceived by conventional assisted reproduction.
Intervention(s): Chorionic villus and cord-blood sampling.
Main OutcomeMeasure(s): Using bisulﬁte pyrosequencing, we have measured average methylation levels of 6 imprinted (LIT1,MEG,
MEST,NESPas, PEG3, and SNRPN), 5 tumor-suppressor (APC,ATM, BRCA1, RAD51C, and TP53), 2 pluripotency (NANOG and OCT4),
and 2 metabolic (LEP and NR3C1) genes, as well as 2 repetitive elements (ALU and LINE1) in 2 tissues of IVM and control neonates.
Using deep bisulﬁte sequencing, we have determined methylation patterns of many individual DNA molecules to detect rare
RAD51C epimutations (allele methylation errors).
Result(s): No statistically signiﬁcant impact was found of IVM on chorionic villus and cord-blood DNA methylation at the studied
developmentally important genes and interspersed repeats. The RAD51C epimutation rate was low (0.5%  0.1%) in all analyzed
samples.Use your smartphoneConclusion(s): IVM-induced epigenetic changes in offspring, if any, are relatively small in
magnitude and/or infrequent. (Fertil Steril 2015;103:720–7. 2015 by American Society for
Reproductive Medicine.)
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720T here has been long-standing in-terest in the epigenetic effectsof various assisted reproductive
techniques (ARTs) and their conse-
quences for the health of offspring.
In vitro maturation (IVM) of human
oocytes is an emerging technique used
to reduce the risk of ovarian hyperstim-
ulation, particularly in women with
polycystic ovary syndrome. BecauseVOL. 103 NO. 3 / MARCH 2015
Fertility and Sterility®maternal methylation imprints are established relatively late
in oocyte development (see 1, 2 for reviews), concerns have
been raised regarding IVM interference with the epigenetic
quality of the oocyte and resulting embryo. Oocytes from
IVM are usually retrieved at the germinal vesicle stage from
small antral follicles (with a diameter of %10 mm) in
nonstimulated or minimally stimulated cycles with (3, 4) or
without (5, 6) a human chorionic gonadotropin trigger.
Cumulus oocyte complexes are cultured in vitro to complete
the ﬁnal steps of maturation and obtain metaphase II
oocytes for in vitro fertilization (IVF) or intracytoplasmic
sperm injection (ICSI). For conventional IVF or ICSI, usually
multiple in vivo matured oocytes are retrieved from
stimulated ovaries. The main advantage of IVM
is avoidance of high doses of gonadotropins and
gonadotropin-releasing–hormone analogues, eliminating
the risk of ovarian hyperstimulation syndrome. This beneﬁt
is particularly important for women suffering from
polycystic ovary syndrome (7, 8).
Although human oocyte IVM was introduced >20 years
ago (9), it has not been widely used in assisted reproduction
(10). Estimates indicate that only 3,000–5,000 of the >5
million children born worldwide from IVF or ICSI have been
conceived by IVM. The restricted application may be largely
a function of the higher rates of miscarriage and the lower
rates of live births after IVM, compared with standard ART
protocols. Several smaller observational studies and non-
randomized clinical trials suggest that birth outcomes and
health for IVM children are comparable to those for children
conceived by conventional IVF or ICSI (11–13). A recent
study (14) reported that weight and height were signiﬁcantly
greater for girls born using IVM than for conventional ICSI
girls, both at birth and after 1 year; however, sample size
was low, and confounding factors could not be excluded.
Compared with the general newborn population, ART
children have a slightly increased rate of birth defects
(15, 16), low birth weight (17), preterm delivery, and
perinatal complications (18, 19). In addition, they may have
an increased risk for some rare imprinting disorders, such as
Beckwith-Wiedemann syndrome (20, 21), most likely owing
to loss of maternal allele methylation (22, 23).
Other ARTs, most importantly ovarian stimulation and
embryo culture, have been associated with abnormal deoxyri-
bonucleic acid (DNA) methylation and gene expression pat-
terns in mouse, ruminants, and humans. In many of these
studies, imprinted genes were used as a model to assess the
epigenetic stability in oocytes, embryos, fetuses, and placentas
(see 1, 2, 24 for reviews). Imprinted genes maintain their
germline-speciﬁc methylation patterns and parent-speciﬁc
activity after fertilization. They are essential for the regulation
of fetal and placental growth, somatic differentiation, and
neurologic and behavioral functions after birth (25, 26).
Limiting dilution bisulﬁte pyrosequencing has been
developed for the methylation analysis of individual or a
few oocytes without any ampliﬁcation bias. The inclusion
of marker genes in multiplex polymerase chain reaction
(PCR) allows the exclusion of somatic DNA contamination
(from damaged cumulus cells); such contamination creates
serious difﬁculties in data interpretation in many studies.VOL. 103 NO. 3 / MARCH 2015Using this sensitive technique, we did not ﬁnd increased rates
of imprinting errors in mouse (27), bovine (28), or human IVM
oocytes (29). Although these results argue in favor of the
notion that imprint establishment is largely correct in human
IVM oocytes, concern remains that maintenance of the
imprinting after fertilization and throughout further develop-
ment may be disturbed. The aim of the present study is to
investigate the stability of functionally important DNA
methylation patterns in IVM newborns, compared with chil-
dren born using conventional IVF or ICSI.MATERIALS AND METHODS
In Vitro Maturation Protocol and Patient Samples
This study was approved by the local ethics committee of the
Ruprecht Karls University, Heidelberg. Informed consent was
obtained from all participating patients. After determination
of levels of follicle-stimulating hormone and estradiol, and
exclusion of ovarian cysts by ultrasound, the inclusion
criteria for IVMwere low estradiol levels and an antral follicle
count ofR7 follicles in each ovary.
A 3-day stimulation with 125 IU per day of subcutaneous
follicle-stimulating hormone (Puregon, Essex Pharma) started
between day 3 and 10 of the cycle. Ovulation induction was
performed 1 or 2 days after stimulation with 250 IU recombi-
nant human chorionic gonadotropin (Ovitrelle, Merck
Serono). Oocytes were retrieved under general anesthesia
33–38 hours later by ultrasound-guided transvaginal punc-
ture. Oocytes were selected immediately after retrieval and
cultivated for 2–3 hours in a lag medium (MediCult IVM Sys-
tem LAG Medium, Origio) and subsequently passed into an
IVMmedium (Final IVMMedium, Origio) for at least 24 hours.
The luteal-phase support was induced on the day of oocyte
retrieval, with orally applied estradiol (6 mg/day; Progynova,
Bayer Vital) and 600 mg/day progesterone, vaginally (Utro-
gest, Dr. Kade/Besins Pharma), starting 1 day later.
Depending on sperm quality, IVF or ICSI was performed
1 day after oocyte retrieval. For ICSI, the cumulus complex
was removed from the oocytes using a solution made from
hyaluronidase raw material of ovine origin (SynVitroHya-
dase, Origio) and mechanical processing. Pronuclei scoring
was done 17–21 hours after IVF or ICSI, and embryo transfer
was performed 3 days after oocyte retrieval. The pregnancy
was tested 12 days after embryo transfer; in cases of
conﬁrmed pregnancy, estradiol and progesterone treatment
continued until week 14.
For each conﬁrmed IVM pregnancy, the next conven-
tional IVF and/or ICSI pregnancies were recruited as controls
at the Department of Gynecological Endocrinology and
Reproductive Medicine. Chorionic villus and cord-blood sam-
ples were obtained from 12 and 21 newborns, respectively,
conceived by IVF or ICSI, with either IVM oocytes or
in vivo matured oocytes (following conventional ovarian hy-
perstimulation). One IVM and 2 control samples with prema-
ture birth (27th gestational week, birth weight%1,000 g) were
excluded from further analysis, resulting in 11 IVM and 19
control samples. Clinical data from parents and offspring
for the analyzed samples are listed in Table 1. One control
pregnancy (no. 17) and 1 IVM pregnancy (no. 21) were721
TABLE 1
Clinically relevant parameters (possible confounding factors) of mother, father, and child.
Case
number
Mother Father Child
Age (y)
Height
(cm)
Weight
(kg) BMI Smoking Age (y) Smoking Fertilization Sex
Gestational
week
Birth
weight (g)
Blood
pH
Controls
1 37 165 77 23.8 No 39 No IVF m 40 3,450 n.a.
2 36 173 63 21.0 No 32 No IVF m 41 3,620 7.36
3 32 164 50 18.6 Yes 32 Yes IVF m 40 3,900 7.31
4 35 160 55 21.5 Yes 34 Yes IVF f 40 3,200 7.24
5 38 169 57 20.0 No 40 No IVF f 40 3,210 7.28
6 38 158 62 24.8 No 37 No IVF m 38 3,220 7.25
7 36 170 60 20.8 Yes 37 No IVF m 41 3,860 7.21
8 38 160 60 23.4 No 47 No IVF m 36 2,240 7.33
9 34 160 52 20.3 No 35 No IVF m 37 2,500 7.33
10 27 170 60 20.8 No 27 No IVF m 39 3,290 7.19
11 39 170 61 21.1 No 40 Yes IVF m 40 3,420 7.17
12 38 173 69 23.1 No 39 No ICSI f 40 4,080 7.09
13 31 168 49 17.4 No 34 No ICSI f 39 3,100 7.35
14 38 168 63 22.3 No 34 No ICSI m 40 3,700 7.07
15 32 160 95 37.1 No 37 Yes ICSI m 40 3,660 7.21
16 27 166 67 24.3 Yes 32 No ICSI m 39 3,780 n.a.
17 38 164 54 20.1 Yes 42 Yes ICSI f 38 3,330 7.22
18 41 164 78 29.0 No 40 Yes ICSI m 40 3,770 7.28
19 30 170 55 19.0 Yes 34 No ICSI f 38 3,290 7.30
Mean  SE 35  4 166  5 62.5  11 22.5  4 32% smokers 36.5  4.5 32% smokers 58% IVF
42% ICSI
68% m
32% f
39  1.5 3.401  447 7.25  0.08
IVM
20 35 162 75 28.6 No 34 No IVF m 37 2,680 7.22
21 30 155 55 22.9 No 34 No IVF m 38 3,300 7.15
22 30 161 52 20.1 Yes 39 Yes IVF f 40 3,170 7.31
23 33 168 108 38.3 No 34 No ICSI f 37 2,570 7.30
24 34 155 48 20.0 No 41 No ICSI f 39 3,060 7.27
25 32 170 113 39.1 No 43 No ICSI m 38 3,150 7.27
26 30 166 52 18.9 Yes 27 Yes ICSI f 41 3,440 7.23
27 33 166 80 29.0 Yes 37 Yes ICSI f 38 2,840 6.89
28 33 166 80 29.0 Yes 37 Yes ICSI f 38 3,010 7.32
29 31 170 75 26.0 No 33 No ICSI m 38 3,475 n.a.
30 31 164 66 24.5 No 38 No ICSI m 38 4,000 n.a.
Mean  SE 32  1.5 164  5 73  21 27  6.5 36% smokers 36  4 36% smokers 27% IVF
73% ICSI
45% m
55% f
38.5  1 3,154  383 7.22  0.13
P value .02 .4 .3 .09 1.0 .9 1.0 .1 .2 .06 .08 .8
Note: For P values, Fisher's exact test was used for dichotomous variables, and the Mann-Whitney U test was used for quantitative variables. f ¼ female; m ¼ male; n.a. ¼ not available.
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Fertility and Sterility®complicated by maternal hypertonus and gestational dia-
betes, respectively.
Fetal placenta samples were collected immediately after
birth. Two tissue cubes, each 5 mm in length, were dissected
from different cotyledons and rinsed with phosphate-
buffered saline, to remove maternal blood. To avoid maternal
decidual contamination, all samples were visually inspected
under a dissection microscope. Chorionic villus samples
(CVS) were frozen at 80C until further use. Blood samples
were stored in EDTA (ethylenediaminetetraacetic acid) tubes
at 20C.
Bisulﬁte Pyrosequencing
Genomic DNA was isolated with the DNeasy Blood and Tissue
Kit (Qiagen), and subsequent bisulﬁte conversion was per-
formed with the EpiTect 96 Bisulﬁte Kit (Qiagen). Polymerase
chain reaction and sequencing primers for bisulﬁte pyrose-
quencing (Supplemental Table 1, available online) were
designed using PyroMark Assay Design 2.0 software (Qiagen).
Polymerase chain reaction ampliﬁcations were performed
with an initial denaturation step at 95C for 5 minutes,
35 cycles at 95C for 30 seconds, primer-speciﬁc annealing
temperature for 30 seconds, and 72C for 45 seconds; a ﬁnal
extension step was completed at 72C for 5 minutes. The re-
action mixture consisted of 2.5 ml of 10 PCR buffer,
20 mM of MgCl2, 0.5 ml of 10-mM dNTP mix (dATP, dCTP,
dGTP and TTP), 1 ml (10 pmol) of each primer, 0.2 ml (1 IU)
of FastStart Taq DNA Polymerase (Roche Diagnostics),
18.8 ml of PCR-grade water, and 1 ml (approximately
100 ng) of template DNA. To reduce technical noise due to
batch effects, all steps were performed in microtiter 96-well
plates containing both IVM and control samples. In addition,
duplicate measurements (technical replicates using the same
bisulﬁte-converted DNA) were performed for each gene and
sample.
Bisulﬁte pyrosequencing (30) was performed on a Pyro-
Mark Q96 MD pyrosequencing system with the PyroMark
Gold Q96 CDT reagent kit (both Qiagen). Pyro Q-CpG software
(Qiagen) was used for data analysis. Only samples in which
both measurements (technical replicates) met the quality
criteria as assessed by the Pyro Q-CpG software (Qiagen/Bio-
tage) were used for statistical analysis. Therefore, the number
of analyzed samples in each group varies among the 17 stud-
ied loci.
Deep Bisulﬁte Sequencing
Next-generation sequencing of bisulﬁte-treated DNA was
used to determine the methylation patterns of several hundred
to several thousand individual alleles of a target gene per sam-
ple in a single experiment (31). To generate amplicon libraries
for the RAD51C promoter, bisulﬁte-treated blood and
placenta DNA samples, respectively, were PCR ampliﬁed using
forward primer CTTGCTTCCTGGCACGAG-ATGGTGTATAA
GTGTGAAAATTTATAAGA and reverse primer CAGGAAA
CAGCTATGAC-CCTCTAAAAATTCCTCAACAATCTAAA. The
primers were tagged with a universal sequences (indicated in
italics) that served as priming sites for a second PCR in which
sample-speciﬁc barcode sequences (multiplex identiﬁers) asVOL. 103 NO. 3 / MARCH 2015well as universal linker (454 adaptor, A- or B-primer, and
key; Roche Diagnostics) sequences were added. Both ﬁrst-
and second-round PCRs were performed with the FastStart
Taq DNA Polymerase system. Brieﬂy, the 12.5-ml reactions
for the ﬁrst PCR contained 0.1 ml (0.5 U) of FastStart Taq
DNA Polymerase, 1.25 ml of 10 PCR buffer with 20 mM
MgCl2, 0.25 ml of 10-mM dNTP mix, 0.5 ml (5 pmol) of each
forward and reverse primer, 0.5 ml of bisulﬁte-treated template
DNA, and 9.4 ml of PCR-grade water. First-round PCR was
conducted with an initial denaturation step of 5 minutes at
95C, followed by 35 cycles at 95C for 1 minute, 60C for
30 seconds, and 72C for 45 seconds; a ﬁnal elongation was
completed at 72C for 7 minutes. The 50-ml reactions for the
second PCR consisted of 0.4 ml (2 IU) of FastStart Taq DNA Po-
lymerase, 5 ml of 10 PCR buffer with 20 mM MgCl2, 1 ml of
10-mM dNTP mix, 2 ml (20 pmol) of each forward and reverse
primer, 3 ml of ﬁrst-round PCR product, and 36.6 ml of PCR-
grade water. The second PCR was performed with an initial
denaturation at 95C for 10 minutes, 35 cycles at 95C for
1 minute, and 72C for 1 minute, followed by a ﬁnal extension
step at 72C for 7 minutes.
Second-round ampliﬁcation products were puriﬁed using
Agencourt AMPure XP Beads (Beckman Coulter) and quanti-
ﬁed using a NanoDrop Spectrophotometer (Peqlab). After
sample pooling, dilution, and emulsion PCR, ampliﬁcation
products were sequenced on a GS Junior System (454 Life Sci-
ences/Roche), following the protocol described in the Emul-
sion PCR Ampliﬁcation Method and Sequencing Method
Manual (Roche). Sequence reads were processed further using
the Amplikyzer programe (32). The analyzed RAD51C ampli-
con provides methylation information on 26 neighboring
CpG (cytosine and guanine separated by a phosphate) sites.Statistical Analyses
Statistical analyses were performed with SPSS versions 21
and 22. The Kolmogorov-Smirnov test was used to test for
normal distribution of the methylation data of a given
gene. Because most data sets were not normally distributed,
the nonparametric Mann-Whitney U test was used to assess
between-group differences. A P value of < .05 was consid-
ered signiﬁcant. For dichotomous variables, such as fertil-
ization method (IVF or ICSI), smoking (yes or no), and
gender (male or female), we applied Fisher's exact test. For
quantitative variables, such as maternal age, body mass in-
dex, gestational age, and birth weight, none of which
showed a normal distribution (Kolmogorov-Smirnov test,
P< .05), the nonparametric Mann Whitney U test was used
to assess between-group differences.
The Spearman's rank correlation was used to test for cor-
relations between individual parental parameters (maternal
body mass index, parental age and smoking) and locus-
speciﬁc DNAmethylation of the offspring. The correlation co-
efﬁcient R can range from 1 (negative correlation) to þ1
(positive correlation). In addition, multivariate analysis of
variance (MANOVA) was used to identify possible effects of
parental factors on the offspring's epigenome. The MANOVA
gives special attention to the correlations between multiple723
ORIGINAL ARTICLE: ASSISTED REPRODUCTIONdependent variables. A Wilks'-lambda of < .05 was consid-
ered signiﬁcant for a between-group difference.RESULTS
To study the possible impact of IVM on the epigenome of
offspring, we quantiﬁed DNA methylation in functionally
important cis-regulatory regions of 6 imprinted (LIT1,
MEG3, MEST, NESPas, PEG3, and SNRPN) genes, 5 tumor-
suppressor (APC, ATM, BRCA1, RAD51C, and TP53) genes,
2 pluripotency (NANOG and OCT4) genes, and 2 metabolic
genes, namely leptin (LEP) and the glucocorticopid receptor
(NR3C1), using bisulﬁte pyrosequencing. Two repetitive ele-
ments, ALU and LINE1, which comprise 10% and 17% of
the human genome, respectively (33), served as surrogate
markers for the detection of global (genome-wide) DNA
methylation changes (34).
Before systematically comparing the methylation proﬁles
of the IVM and control groups, we tested for possible con-
founding factors. The following clinical parameters were
considered: maternal age, weight, height, body mass index,
and smoking, paternal age and smoking, as well as fertilization
method, sex, gestational age, birth weight, and blood pH of the
child (Table 1). Maternal age was signiﬁcantly lower (Mann-
Whitney U test; P¼ .02) in the IVM (32  1.5 years) than in
the control group (35  4 years). Other covariables did not
differ signiﬁcantly between groups. Because of the small sam-
ple size, we did no further subgrouping (e.g., based on mode of
conception, sex, etc.) of the IVM and control samples, yielding
a maximum of 11 independent CVS and blood samples,
respectively, in the IVM group, and 19 in the control group.
Bisulﬁte pyrosequencing was used to measure the
average methylation levels of millions of target molecules
in genomic DNA samples. According to the Kolmogorov-TABLE 2
Methylation values (mean and SE) of 15 developmentally important gene
Imprinted genes Tumor-
LIT1 MEG3 MEST NESPas PEG3 SNRPN ATM APC B
Blood
Control
No. 19.0 18.0 15.0 18.0 18.0 16.0 14.0 18.0
Mean 46.1 46.1 39.1 39.1 41.2 38.5 1.7 3.8
SE 0.8 2.7 0.7 0.7 0.8 0.4 0.2 0.1
IVM
No. 11.0 10.0 11.0 11.0 11.0 10.0 8.0 11.0
Mean 46.2 48.5 39.1 39.3 43.0 38.3 1.9 4.0
SE 0.4 0.9 1.0 0.4 0.6 0.6 0.2 0.2
CVS
Control
No. 19.0 19.0 17.0 19.0 19.0 17.0 15.0 17.0
Mean 46.7 33.6 38.7 35.6 43.1 41.8 1.6 40.5
SE 0.4 2.7 0.3 1.0 0.6 1.6 0.2 2.6
IVM
No. 11.0 10.0 11.0 11.0 11.0 10.0 6.0 10.0
Mean 46.9 37.9 38.5 33.7 42.9 44.2 1.5 40.0
SE 0.3 5.0 0.5 3.5 0.8 2.1 0.2 4.0
Note: None of the analyzed sequences or tissues showed a signiﬁcant (Mann-Whitney U test) diffe
Pliushch. DNA methylation analysis of IVM neonates. Fertil Steril 2015.
724Smirnov test, the methylation data sets of the studied loci
were not normally distributed. Using the nonparametric
Mann-Whitney U test, none of the 15 developmentally
important genes, and none of the 2 repeats revealed a signif-
icant methylation difference between IVM children and the
control group in either of the 2 tissues (Table 2). The observed
differences between the IVM group and controls were on the
order of 1 percentage point, which is within the limits of nat-
ural variation. The ﬁndings were the same for comparison of
the combined methylation data sets of (imprinted, tumor-
suppressor, pluripotency, and metabolic) genes with similar
function.
Slight changes in mean methylation, i.e., of a tumor-
suppressor gene, could be due to an increased rate of
single-CpG methylation errors at random positions of many
DNA molecules or to allele methylation errors affecting all
or most CpGs on a few individual DNAmolecules. As the den-
sity of methylated CpGs, rather than individual CpGs, is what
usually turns a gene ‘‘on’’ or ‘‘off,’’ only alleles with a majority
of CpGs aberrantly methylated are considered epimutations,
whereas single CpG errors are most likely without functional
consequences (35, 36). To compare the epimutation rate of a
representative tumor-suppressor gene in IVM samples vs.
controls, we performed deep bisulﬁte sequencing of the
RAD51C promoter in CVS and blood samples. On average,
each blood sample yielded 1,294 (range: 494–2,321) reads
in controls and 1,297 (628–2,258) in the IVM group; CVS
yielded 1,716 (452–2,459) and 1,615 (484–2,484) reads,
respectively (Table 3).
The mean RAD51C methylation (number of methylated
CpGs divided by the total number of CpGs in all analyzed al-
leles) was very low (0.3%–1.1%) in all samples. For epimuta-
tion analyses, alleles without single-CpG methylation errors
were considered normal; alleles with R50% aberrantlys and 2 repeats in cord blood and CVS.
suppressor genes
Pluripotency
genes
Metabolic
genes
Repetitive
elements
RCA1 RAD51C TP53 NANOG OCT4 LEP NR3C1 ALU LINE1
16.0 18.0 14.0 19.0 18.0 15.0 15.0 19.0 18.0
1.7 1.8 1.5 89.9 83.6 16.3 2.9 23.0 74.6
0.2 0.2 0.2 0.8 1.2 0.7 0.2 0.4 4.4
11.0 10.0 8.0 11.0 11.0 10.0 10.0 11.0 10.0
1.5 2.1 1.5 89.4 79.5 17.3 2.5 23.2 78.5
0.2 0.3 0.2 0.7 1.6 0.8 0.2 0.4 0.5
19.0 19.0 10.0 13.0 19.0 17.0 18.0 19.0 17.0
1.9 1.9 2.2 82.4 56.8 35.0 2.4 21.4 45.9
0.1 0.2 0.3 0.8 2.6 2.5 0.1 0.3 0.7
11.0 11.0 10.0 11.0 11.0 10.0 11.0 11.0 11.0
1.9 1.6 1.3 82.3 56.6 29.6 2.5 21.0 40.0
0.2 0.2 0.2 0.8 3.9 2.6 0.2 0.4 6.0
rence between IVM and control samples.
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TABLE 3
Number and methylation patterns of RAD51C alleles analyzed by deep bisulﬁte sequencing.
Case
number
Cord blood Placenta
Number
of reads
Normal
alleles
(%)
Mixed
alleles
(%)
Abnormal
alleles
(%)
Mean
methylation (%)
Number
of reads
Normal
alleles
(%)
Mixed
alleles
(%)
Abnormal
alleles
(%)
Mean
methylation (%)
Controls
1 733 85.3 14.7 0 0.7 2,233 85.9 14.2 0 0.6
2 494 87.7 12.6 0 0.5 2,459 88.5 11.5 0 0.5
3 844 87.2 12.8 0 0.5 2,119 88.5 11.5 0 0.5
4 873 90.0 10.0 0 0.4 1,750 85.1 14.7 0.2 0.8
5 762 89.4 10.6 0 0.6 2,000 87.1 12.9 0 0.5
6 2,287 88.7 11.3 0 0.5 2,367 88.2 11.8 0 0.5
7 1,775 92.1 7.9 0 0.3 1,707 89.3 10.7 0 0.4
8 1,595 89.7 10.3 0 0.5 1,612 89.4 10.6 0 0.4
9 1,672 87.6 12.3 0.1 0.9 730 89.6 10.6 0 0.4
10 1,415 87.5 12.5 0 0.5 452 85.2 14.8 0 0.6
11 1,582 88.7 11.3 0 0.5 691 86.8 13.2 0 0.6
12 827 89.6 10.4 0 0.4 2,217 89.1 10.9 0 0.4
13 811 89.6 10.4 0 0.4 2,270 86.2 13.8 0 0.6
14 797 89.3 10.7 0 0.4 1,891 88.1 11.9 0 0.5
15 974 89.7 10.3 0 0.4 1,979 90.6 9.4 0 0.4
16 2,321 89.8 10.2 0 0.4 1,811 85.4 14.6 0 0.6
17 1,466 88.6 11.4 0 0.5 1,403 90.0 10.1 0 0.4
18 1,226 88.9 11.0 0.1 0.6 2,051 88.9 11.1 0 0.5
19 2,130 90.6 9.2 0.2 0.5 859 87.3 12.7 0 0.5
IVM
20 810 87.0 13.0 0 0.6 2,484 86.4 13.6 0 0.6
21 781 88.5 11.5 0 0.5 1,891 89.3 10.7 0 0.4
22 1,714 90.0 9.9 0.1 0.3 2,047 87.0 13.0 0 0.5
23 826 88.2 11.6 0 0.5 2,171 86.7 13.3 0 0.6
24 628 84.6 15.6 0 0.6 2,454 87.2 12.8 0 0.6
25 2,258 89.2 10.8 0 0.5 2,377 89.3 10.7 0 0.4
26 1,564 88.1 11.8 0.1 0.6 827 86.7 13.3 0 0.5
27 1,958 89.1 10.3 0.6 1.1 484 84.9 15.1 0 0.6
28 1,168 89.5 10.5 0 0.5 761 84.4 15.6 0 0.6
29 1,557 91.6 8.4 0 0.3 784 88.0 12.0 0 0.5
30 1,425 90.6 9.3 0.1 0.5 848 84.4 15.6 0 0.7
Note: Normal alleles do not contain any CpG error. Mixed alleles contain single CpG errors, but the majority (>50%) of CpGs are correctly demethylated. In abnormal alleles, the majority of CpGs
show aberrant methylation.
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Fertility and Sterility®methylated CpGs were considered abnormal (epimutations).
Mixed alleles were those containing R1 but <50% methyl-
ated CpG sites (Table 3). In the vast majority of mixed alleles,
only 1 or a few of the 26 analyzed CpG sites were methylated.
The Mann-Whitney U test did not show signiﬁcant differ-
ences in the percentages of abnormal, mixed, and/or normal
alleles between IVM neonates and controls in either of the 2
tissues. Most (15 of 19 control, and 7 of 11 IVM) samples
did not show a single epimutation in either analyzed tissue.
In the remaining samples, the epimutation rate ranged from
0.1% to 0.6%.
As we did not ﬁnd any epigenetic differences between
IVM neonates and controls, the blood and CVS methylation
data sets, respectively, of all 30 analyzed neonates were com-
bined to identify other clinical parameters (maternal body
mass index, parental age and smoking, mode of conception,
sex, gestational age, birth weight, and blood pH) inﬂuencing
the offspring's epigenome. Using Spearman's rank correlation
test, the only covariable showing some slight-to-moderate
correlations was parental smoking (R ¼ .6 for maternal and
R¼ .7 for paternal smoking with imprinted gene methylation)
in blood, but not placenta, DNA.VOL. 103 NO. 3 / MARCH 2015In addition, we performed aMANOVAwith all known co-
variables to identify possible effects on the offspring's epige-
nome. Considering Wilks' lambda < .05 to be signiﬁcant, we
did not ﬁnd any effects of parental smoking or other clinical
factors on cord-blood methylation (bisulﬁte pyrosequencing
measurements), either for individual genes and repeats, or
for (imprinted, tumor-suppressor, pluripotency, and meta-
bolic) gene panels. The ﬁndings were the same when the per-
centage of normal, mixed, and abnormal RAD51C alleles
were used as dependent variables.DISCUSSION
Since the introduction of IVF in 1978, and of ICSI in the early
1990s, the application of ARTs for human infertility treatment
has increased dramatically, accounting for up to several
percent of all live births in many developed countries. Despite
a small increase in the risk of adverse perinatal outcome (18,
19) and birth defects (15, 16), human ARTs are generally
considered safe. Epigenetic defects associated with parental
infertility, and/or induced by various ARTs, may contribute
to medical problems of the offspring. Many studies in725
ORIGINAL ARTICLE: ASSISTED REPRODUCTIONanimal models have convincingly shown that superovulation
and embryo culture can induce aberrant methylation
patterns, e.g., by interfering with the maintenance of
methylation imprints, and persistent changes in gene
regulation (see 1, 2, 24 for reviews). Because gametogenesis
and embryogenesis exhibit considerable species differences,
in particular between humans and rodents, experimental
ﬁndings in animal models cannot be directly extrapolated
to the human situation.
Evidence for epigenetic effects of ARTs in humans is
limited. Although ART-induced epigenetic defects have
been reported in human superovulated and IVM oocytes, as
well as in surplus embryos (see 1, 2, 37 for reviews), the
sample size in many of these studies is low, and moreover,
we do not know the epigenetic variation of oocytes and
embryos from fertile couples. In addition, when working
with small amounts of bisulﬁte-treated DNA, excluding arti-
facts due to somatic DNA contamination and/or an ampliﬁca-
tion bias is difﬁcult. Several studies have reported epigenetic
differences between ART and non-ART children (38–41),
whereas others have not (42, 43). Again, small sample size
and the enormous extent of epigenetic variation among
normal individuals render interpretation difﬁcult.
To assess the epigenetic effects of IVM compared with
conventional ART treatment, we have analyzed the methyl-
ation levels of 15 developmentally important genes and 2
repeat families in 2 different tissues: CVS and cord blood.
We have employed bisulﬁte pyrosequencing, which is the
most accurate method for quantitative determination of
mean methylation of many DNA molecules. None of the 15
studied functionally relevant cis-regulatory (promoter and
imprinting control) regions, or global DNA methylation
(assessed with the use of ALU and LINE1 repeats) differed
signiﬁcantly between the IVM and control groups.
In contrast to bisulﬁte pyrosequencing, deep bisulﬁte
sequencing can generate methylation information on many
individual DNA molecules (from various tissues and
individuals) in a single experiment. Because DBS can distin-
guish between normally and abnormally methylated alleles,
it detects rare epimutations in a much larger pool of normal
alleles (ﬁnding ‘‘needles in a haystack’’). A representative
tumor-suppressor gene, RAD51C, was chosen for DBS anal-
ysis because even a low level of epimutations (hypermethy-
lated alleles) in healthy body cells can serve as the ﬁrst hit
of tumor development. Constitutive BRCA1 and RAD51C ep-
imutations (in varying percentages of cells from various
healthy tissues) account for a small number of mutation-
negative cases of hereditary breast and ovarian cancer (44).
In vitro methylation and transfection assays showed that
repression of the BRCA1 tumor-suppressor gene directly
depends on the number of methylated CpGs in its promoter
region (45). Therefore, a plausible assumption is that the
risk of developing cancer correlates with the percentage of
hypermethylated alleles. Consequently, any increase in the
epimutation rate of tumor-suppressor genes should be a cause
for concern. A reassuring ﬁnding was that the frequency of
RAD51C epimutations was very low (0.5%  0.1%) in both
analyzed tissues of all IVM and control samples, with the ma-
jority of samples showing no epimutations.726Imprinted genes, which acquire their methylation pat-
terns during late oocyte development (1, 2), are frequently
used as models for studying IVM-induced epigenetic changes
in oocytes (24, 27–29); however, the interpretation of DBS
data in somatic tissues is more difﬁcult. Because imprinted
genes are differentially methylated, quantiﬁcation of
somatic epimutations requires a single-nucleotide polymor-
phism to distinguish between the 2 parental alleles. Moreover,
imprinted genes can show considerable methylation variation
among normal individuals (46, 47), and the functional
consequences of methylation changes on the order of
several percentage points remain to be elucidated.
Although our study suffers from the small sample size
(11 IVM vs. 19 control children), it is the ﬁrst systematic
epigenetic analysis of IVM children, employing 2 techniques
for measuring average DNA methylation and single–DNA
molecule methylation. Although we cannot exclude minor
epigenetic changes, all measurements in IVM children were
within the normal range of methylation variation. Multivar-
iate analysis of variance did not provide evidence for parental
factors with large effects on the methylation patterns of the
studied loci. Although increasing the sample size in the
next few years is desirable, reaching genetic-study standards
using tissues from human IVM newborns and children will
not be possible. However, our failure to detect major epige-
netic effects in IVM children compared with those from con-
ventional ART treatment provides reassurance regarding the
epigenetic safety of human IVM protocols. So far, neither
human IVM oocytes (29), nor IVM newborns have exhibited
gross epigenetic abnormalities that can be associated with
disease.REFERENCES
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SUPPLEMENTAL TABLE 1
Genes and primers for bisulﬁte pyrosequencing.
Gene Primer Sequence (50-30)
Amplicon
length (bp) Chromosomal localization (bp) No. of CpGs
Imprinted genes
LIT1 Forward AATTAGTAGGTGGGGGG 122 Intronic ICR2 2
Reversea CTAAAAAACTCCCTAAAAATC CpG island
Sequencing GGGGGTAGTYGGAG Chr.11: 2,699,945–2,700,067
MEG3 Forward GATTTTTTTTATATATTGTGTTTG 220 50 upstream promoter 3
Reversea CTCATTTCTCTAAAAATAATTAACC Secondary DMR, CpG island
Sequencing GTGTTTGAATTTATTTTGTTTGG Chr.14: 100,825,817–100,826,037
MEST Forwarda TYGTTGTTGGTTAGTTTTGTAYGGTT 219 Intron/exon-spanning DMR 5
Reverse CCCAAAAACAACCCCAACTC CpG island
Sequencing AAAACAACCCCAACTC Chr. 7: 130,492,225–130,492,444
NESPas Forwarda GATGAAGGGGTGGTTAGTA 229 Exonic ICR 4
Reverse CCAAAAATACCTTCTTAACCTTAA CpG island
Sequencing TAAACTAAAAACTCTCAAAT Chr. 20: 58,854,960–58,855,189
PEG3 Forward GGTGTAGAAGTTTGGGTAGTTG 153 50 upstream ICR
Reversea CTCACCTCACCTCAATACTAC
Sequencing TGTTTATTTTGGGTTGGT Chr. 19: 56,840,576–56,840,729
SNRPN Forwarda AGGGAGTTGGGATTTTTGTATT 237 ICR 3 þ 3
Reverse CCCAAACTATCTCTTAAAAAAAAC CpG island
Sequencing 1 ACACAACTAACCTTACCC Chr. 15: 24,954,865–24,955,102
Sequencing 2 CCAACCTACCTCTAC
Tumor-suppressor genes
APC Forwarda GGTTAGGGTTAGGTAGGTTGT 193 Intronic promoter 1A 7
Reverse ACTACACCAATACAACCACATATC
Sequencing CCACACCCAACCAA Chr. 5: 112,737,678–112,737,871
ATM Forward GAGGGTGGGTGAGAGTTT 124 50 upstream promoter 6
Reversea AACACTACCCCAAAACATT (þstrand)
Sequencing GTTGGTTATTGGTGGA Chr.11: 108,222,814–108,222,938
BRCA1 Forward ATTTAGAGTAGAGGGTGAAGG 232 50 upstream promoter 5
Reversea TCTATCCCTCCCATCCTCTAATT (þstrand)
Sequencing TTGAGAAATTTTATAGTTTGTTTT Chr. 17: 43,125,274–43,125,506
RAD51C Forward ATGGTGTATAAGTGTGAAAATTTATAAGA 292 50 upstream promoter 7
Reversea CCTCTAAAAATTCCTCAACAATCTAAA (þstrand)
Sequencing GTAAAGTTGTAAGGT Chr. 17: 58,692,472–58,692,764
TP53 Forward TTTTTTGGGAGTAGGTAGAAGAT 220 50 upstream promoter 4
Reversea AAAAACCTTCTAACCTTTCAC (þstrand)
Sequencing TGAAAGTATTGTGTTTTTTAGTA Chr. 17: 7,688,327–7,688,547
Pluripotency genes
NANOG Forward TTAATTTATTGGGATTATAGGGGTG 164 50 upstream promoter 3
Reversea AAACCTAAAAACAAACCCAACAAC
Sequencing GGATTATAGGGGTGG Chr. 12: 7,789,065–7,789,229
OCT4 Forward AAGTTTTTGTGGGGGATTTGTAT 185 50 upstream promoter 2 þ 1
Reversea CCACCCACTAACCTTAACCTCTA
Sequencing 1 TGAGGTTTTGGAGGG Chr. 6: 31,170,705–31,170,890
Sequencing 2 GTTATTATTATTAGGTAAATATTTT
Metabolic genes
LEP Forward GGAGTTTTTGGAGGGATATTAAGGATT 417 50 upstream promoter 6
Reversea CTACATCCCTCCTAACTCAATT CpG island
Sequencing GGGAGGTATTTAAGGGTG Chr. 7: 128,240,997–128,241,414
NR3C1 Forwarda AATTTTTTAGGAAAAAGGGTGG 405 Exon 1F promoter 8
Reverse CCTTCCCTAAAACCTCCC Intronic CpG island
Sequencing AAATAACACACTTCA Chr. 5: 143,403,940–143,404,344
Repetitive elements
ALU Forward GGGACACCGCTGATCGTATAb Approx. 150 All chromosomes Approx. 3
TTTTTATTAAAAATATAAAAATTAGT Interspersed repeat
Reverse CCAAACTAAAATACAATAA
Universala GGGACACCGCTGATCGTATA
Sequencing AATAACTAAAATTACAAAC
LINE1 Forward TTTTGAGTTAGGTGTGGGATA Approx. 245 All chromosomes Approx. 4
Reversea CTCACTAAAAAATACCAAACAA Interspersed repeats
Sequencing GTTAGGTGTGGGATATAGTT
Note: The chromosomal localization column entries are according to Ensembl version 76. Approx.¼ approximately; bp¼ base pairs; Chr.¼ chromosome; DMR¼ differentially methylated region;
ICR ¼ imprinting control region.
a Biotinylated primer.
b Linker sequence that is recognized by the biotinylated universal primer.
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